Highlights in bladder cancer at ESMO 2022

Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, discusses the hot topics in bladder cancer at ESMO 2022, including potential novel biomarkers and the results from Cohort K of the EV-103 trial (NCT03288545). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.